SCOTT CUNNINGHAM: Open Payments
NPI 1568403624 · JAMESTOWN, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,693 in 192 payments from 16 companies in 2025. Trend: 2023 $1,356 · 2024 $1,958 · 2025 $2,693
Food & beverage: $2,693
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 25 | $378 |
| Otsuka America Pharmaceutical, Inc. | 29 | $374 |
| Teva Pharmaceuticals USA, Inc. | 31 | $353 |
| Axsome Therapeutics, Inc. | 13 | $272 |
| Alkermes, Inc. | 17 | $236 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 20 | $190 |
| Vanda Pharmaceuticals Inc. | 6 | $187 |
| Lundbeck LLC | 20 | $182 |
| Supernus Pharmaceuticals, Inc. | 11 | $160 |
| Neurocrine BioSciences, Inc. | 6 | $116 |
Products named: VRAYLAR, REXULTI, Auvelity, ARISTADA, CAPLYTA, FANAPT, ABILIFY ASIMTUFII, UZEDY.
Industry payments across NY — which companies pay providers there.
